NeoLumina bio

About Us

Our Mission

We aim to design psychedelic-inspired therapeutics that offer greater predictability and control to increase effectiveness in treating mental health disorders.

With the rapidly rising global prevalence of eating disorders, anxiety and depression, and other mental health disorders, one of our goals is to develop effective treatments based on psilocybin and psilocin that remove the psychedelic effects; but have greater efficacy and fewer harmful side-effects than current drugs on the market.

Our first product candidate, a proprietary psilocybin-based oral capsule, is being prepared to enter human trials for eating disorders and our novel psilocybin and psilocin analogs will be eligible for patenting which would establish a valuable intellectual property portfolio.

Product Development

N

Advance our lead psilocybin-based product candidate to human studies

N

Continue proprietary natural molecule production and development

N

Create new molecules (analogs of psilocybin and psilocin) that are eligible for composition of matter patents and retain the beneficial effects of the natural molecules but with controlled or reduced hallucinogenic effects

Initial Areas of Focus

Our 4 initial areas of focus have been strategically selected as they offer the greatest market reach and potential impact.

EATING DISORDERS (ANOREXIA, BULEMIA, BINGE EATING)
  • Eating disorders represent the deadliest of all mental health disorders (Current Psychiatry Reports, 2020)
  • There are currently few drugs available to use for eating disorders 
  • It is estimated that 9% of the global population suffers from an eating disorder, so approximately 700 million people globablly and almost 30 million people in the US (National Association of Anorexia Nervosa and Associated Disorders)

Led by Dr. Wendy Oliver-Pyatt, MD – Director, International Association of Eating Disorder Professionals

Depression, Anxiety, Post Traumatic Stress Disorder (PTSD)
  • Approximately 700 million to 1 billion people globally suffer from anxiety, depression, and/or PTSD
  • Current drug treatments have limited efficacy and several negative side effects

Led by Dr. Mark Gold, MD – Distinguished Professor, Psychiatry, University of Florida

Alcohol and Drug Addiction
  • Affects approximately 300 million people worldwide annually
  • Only 10% of people addicted receive treatment

Led by Dr. Kevin Hill, MD – Addiction psychiatrist, Director of the Division of Addiction Psychiatry at Harvard’s Beth Israel Deaconess Medical Center, and an Associate Professor of Psychiatry at Harvard Medical School.

Pain
  • Approximately 800 million people globally suffer from chronic pain
  • More than 80% of patients with chronic pain are affected by severe depression

Led by Dr. Eduardo Muñoz, MD, PhD – Professor, Immunology, University of Córdoba

Learn More About Our Strategic Partners

We’ve strategically partnered with global experts in drug development and mushroom spawn cultivation technology.

UNESP and FEPAF

Our exclusive partnership with FEPAF and UNESP brings an expert team of PhD scientists in bio-engineering, drug discovery and development. Learn more about our expert team here.

UNESP – São Paulo State University (UNESP, Portuguese: Universidade Estadual Paulista “Júlio de Mesquita Filho”) – is ranked one of the top 100 “Young” universities (under 50 years old), and 11th best universities in emerging countries by UK publication Times Higher Education.

FEPAF – Foundation for Agricultural and Forestry Studies and Research

Lambert Joint Venture (60% NeoLumina / 40% Lambert)

Founded in 1919, the Lambert Spawn Company has led the way in the mushroom industry for its first century in America. Leaders in technical achievement, commitment to mushroom growers, and dedication to the industry as a whole will continue to make Lambert the leader into the next century.

www.lambertspawn.com

Joint Venture (60% NeoLumina / 40% Lambert)

NeoLumina has joined Lambert Spawn to leverage their 100+ years of mushroom experience,, specifically spawn production, knowledge and expertise including:

  • Initiating an IP program to produce higher concentrations of the active natural compounds, psilocybin and psilocin from mycelium versus fruiting bodies for lower commercial production cost
  • Proprietary production methodology can be used to create active pharmaceutical ingredients for other products in the future

General Inquiries

Investor Relations